Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday.

Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ahead of expected updates from an upcoming AI conference in Dubai.

Next Wednesday, October 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) cofounder and CEO Chris Gibson is set to speak at an AI conference, where he is expected to tackle the company’s approach to generating data, automating experiments, and using AI and machine learning for its discoveries.

Investors will also closely watch out for cues on Recursion Pharmaceuticals, Inc.’s (NASDAQ:RXRX) expansion plans and business outlook over the next few years.

Just recently, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) received a pessimistic comment from former hedge fund manager and Mad Money host, Jim Cramer, saying, it has done “absolutely nothing.”

“I need to see a proof of concept here. I absolutely know that NVIDIA’s in it, but …we need to see something good before I tell you I would put any money in it,” he said.

“We’re going to have to hold off. I gotta meet them face to face and see what’s going on,” he added.

While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.